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Objective: To observe the protective effect of breviscapine on mice with cisplatin-
induced nephrotoxicity.
Methods: Mice were given a single injection of cisplatin (8 mg/kg, i.p.); then, bre-
viscapine was given to mice at 25 mg/kg and 50 mg/kg doses, respectively, once a day for
seven days. Renal tissue structure was observed after animals were sacriﬁced. Blood urea
nitrogen (BUN), serum creatinine (Scr), lipid peroxide (MDA) and superoxide dismutase
(SOD) serum levels were detected; and MDA, glutathione peroxidase, and SOD levels in
the renal cortex were detected.
Results: Compared with the blank control group (BCG), the kidney pathological damage
of mice in the model control group (MCG) was more severe. After applying different
doses of breviscapine, different degrees of renal injury improvement appeared. Compared
with the BCG, the serum levels of Scr and BUN in the MCG increased to (89.92 ± 6.78)
mmoL/Land (15.32 ± 4.53) mmoL/L. The differences were statistical signiﬁcant
(P < 0.01). Compared with the MCG, the serum levels of Scr and BUN in the Bre low-
dose groups and Bre high-dose groups decreased signiﬁcantly (P < 0.05). Compared with
the BCG, the MDA levels in serum and in the renal cortex in the MCG signiﬁcantly
increased, while the SOD levels signiﬁcantly decreased. Both the differences were sta-
tistically signiﬁcant (P < 0.01). In the Bre low-dose groups and Bre high-dose groups,
MDA levels in serum and in the renal cortex signiﬁcantly decreased, while SOD and
glutathione peroxidase levels in the renal cortex signiﬁcantly increased, compared with
the MCG; and the differences were statistically signiﬁcant (P < 0.05).
Conclusions: Breviscapine can reduce cisplatin-induced renal toxicity in mice and it's
possible through inhibition of renal tubule cell lipid peroxidation and reduces the
nephrotoxicity of cisplatin.1. Introduction
Cisplatin is a common cycle nonspeciﬁc clinical platinum
anticancer drug that has achieved a satisfactory antineoplastic
effect in the treatment of a variety of solid tumors [1,2]. Cisplatin
is involved in approximately 80% of antineoplastic combined
chemotherapy protocols. Since the antineoplastic effect of
cisplatin is dose dependent, high doses would lead to renalinjury, gastrointestinal reactions, ototoxicity and peripheral
neuropathy [3,4]. The high aggregation, hypermetabolism and
discharge characteristics of cisplatin in kidneys may cause
acute or chronic renal injury; and although hydration treatment
can prevent the nephrotoxicity of cisplatin to some extent,
renal dysfunction appears in approximately 25%–30% of
patients after reaching a dosage of 80 mg/cm2 [5]. Renal
toxicity is a main obstacle in the clinical usage of cisplatin,
and determining how to control renal toxicity while retaining
the antineoplastic effect of cisplatin is the main focus in
clinical researches. Breviscapine (Bre) is a kind of ﬂavonoid
extracted from the compositae plant, erigeron breviscapus;
which has shown anti-microbial, anti-inﬂammatory, free
radical-eliminating and antineoplastic effects [6,7]. A study has
reported its curative effect in the treatment of diabetic and
hypertensive nephropathy [8], but whether it has a protectiveen access article under the CC BY-NC-ND
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In this study, a cisplatin-induced Kunming mice nephropathy
model was established; then, pathological sections and blood
biochemistry were analyzed to investigate the effect of Bre on
renal toxicity, and explore its mechanism.
2. Materials and methods
2.1. Drugs and reagents
Bre lyophilized powder (50 mg/bottle) was purchased from
Hunan Hangseng Pharmaceutical Co., Ltd. (20100403).
Cisplatin lyophilized powder (20 mg/bottle) was purchased from
Shandong Qilu Pharmaceutical Product (908027 CF). Creatinine
(Scr) test kit, blood urea nitrogen (BUN) test kit, malondialde-
hyde (MDA) detection kit, and superoxide dismutase (SOD)
detection kit were supplied by Nanjing Jiancheng Biological
Engineering Co., Ltd. Other reagents were all pure analysis.
2.2. Animals and equipment
Equal numbers of male and female Kunming mice, weighting
18–22 g, were purchased from the Medical Experimental Animal
Center of Henan Province; and were used in the experiment. The
752N ultraviolet visible spectrophotometer was provided by
Shanghai Precision and Scientiﬁc Instrument Co., Ltd. The TL80-1
medical centrifuge was obtained from Jiangsu JiangyanTianli
Equipment Co., Ltd. The AU2700 automatic biochemical analyzer
andBX40opticalmicroscopewere obtained fromOlympus, Japan.
2.3. Groups and drugs
Kunming mice were randomly divided into four groups ac-
cording to weight with 12 mice in each group: (1) blank control
group (BCG), mice were routinely fed and lavaged with 0.5%
CMC-Na solution; (2) model control group (MCG), a cisplatin-
induced renal injury in mice model was established by intra-
peritoneally injecting cisplatin lyophilized powder diluted with
8 mg/kg of saline water, and mice were lavaged with 0.5%
CMC-Na solution; (3) Bre low-dose group (BLDG), after a
nephropathy model was established, mice were lavaged with a
Bre mixed suspension (0.5% CMC-Na) at 25 mg/kg; (4) Bre
high-dose group (BHDG), after a nephropathy model was
established, mice were lavaged by a Bre mixed suspension
(0.5% CMC-Na) at 50 mg/kg. After establishing a nephropathy
model, Bre was administered to all animals once a day for seven
days, with a drug delivery volume of 0.1 mL/10 g.
2.4. Observation of kidney morphology
On the eighth day, two mice were randomly selected from
each group, and sacriﬁced by dislocation. Kidneys were taken
out by caesarean section. Kidney tissues were ﬁxed with 10%
formalin, embedded in parafﬁn, sliced in a parafﬁn slicing ma-
chine, and H&E staining was performed. Shape and structure of
kidney tissues were observed under a light microscope.
2.5. Preparation and determination of samples
After administering ether anesthesia, blood was collected
from the angular vein of mice and placed into a tube withheparin anticoagulant, centrifuged at 3000 r/min for 10 min,
and stored in a refrigerator at −4 C. Mice were sacriﬁced,
kidneys were quickly removed and placed in a refrigerator
at −40 C, frozen kidneys were taken out, small renal cortical
tissues were chipped in the ice bath, 0.1 moL/L of PBS so-
lution (pH = 7.4, 4 C) was added, 10% of the renal cortical
tissue homogenate was made by grinding, centrifuged at
3000 r/min for 10 min, and the liquid supernatant was placed
in a refrigerator at −4 C.Scr and BUN were determined using
an automatic analyzer. MDA, SOD and glutathione peroxi-
dase (GSH-Px) were analyzed according to the kit's
instructions.
2.6. Statistical analysis
Results were expressed as mean ± SEM. SPSS 11.0 was used
for statistical analysis. One-way analysis of variance and t-test
comparison were applied in the statistical analysis. P < 0.05 was
considered signiﬁcant.
3. Results
3.1. Cisplatin-induced kidney structural changes in mice
H&E staining results revealed that kidney structure was
normal and renal tubular and glomerular structures were clear
in the BCG. Compared with the BCG, mice in the MCG had
severe renal pathological injury, renal tubular epithelial cell
swelling occurred, cell vacuolization, necrosis, and shedding
appeared, ﬁbrous tissue proliferated in the renal interstitium,
inﬁltration of a large number of inﬂammatory cells occurred,
and parts of the brush-border were damaged. After applying
different doses of Bre, renal injury improved in different de-
grees. In the BLDG, renal tubules were slightly swollen, and
necrosis occurred in some renal tubules. The ﬁbrous hyper-
plasia in renal interstitium was not obvious, with a small
amount of inﬂammatory cell inﬁltration, and some parts of the
brush-border fell off. In the BHDG, renal tissue structure was
basically normal, and only the renal tubules were slightly
swollen. The renal interstitium was normal (As shown by the
arrows in Figure 1).
3.2. Effect of Bre on GSH-Px serum activity in cisplatin-
induced renal injury mice
GSH-Px activity decreased in the MCG, compared with the
BCG; and the difference was statistically signiﬁcant
(P < 0.05). GSH-Px activity in the BLD and BHDGs remained
much lower than the BCG, but was signiﬁcantly improved in
the MCG; and the difference was statistically signiﬁcant
(P < 0.05) (Figure 2).
3.3. Effect of Bre on Scr and BUN serum levels in
cisplatin-induced renal injury in mice
Scr and BUN serum levels signiﬁcantly improved in the
MCG (P < 0.01), compared with the BCG; while Scr and BUN
serum levels in the BLD and BHDGs signiﬁcantly increased,
compared with the MCG (P < 0.05). These results indicate that
cisplatin can induce renal injury, while Bre can alleviate renal
injury in a dose dependent manner (Table 1).
Figure 1. H&E staining of mouse renal structure (×100). (A) BCG; (B) MCG; (C) BLDG; (D) BHDG.
Figure 2. Effect of Bre on GSH-Px serum activity in cisplatin-induced
injury mice. Compared with the BCG, #P < 0.05; compared with the
MCG, *P < 0.05.
Table 3
Effect of Bre on MDA and SOD levels in cisplatin-induced renal cortex
injury in mice (mean ± SD, n = 10).
Group Dose (mg/kg) SOD (U/g/pro) MDA (nmoL/g/pro)
BCG – 9.28 ± 1.32 6.21 ± 1.21
MCG 8.00 3.98 ± 0.48## 11.61 ± 1.62##
BLDG 25.00 5.68 ± 0.71* 7.87 ± 1.41*
BHDG 50.00 5.72 ± 0.83* 8.11 ± 0.98*
Compared with the BCG, #P < 0.05, ##P < 0.01; compared with the
MCG, *P < 0.05, **P < 0.01.
Table 1
Effect of breviscapine on Scr and BUN serum levels in cisplatin-induced
renal injury in mice (mean ± SD, n = 10).
Group Dose (mg/kg) BUN (mmoL/L) Scr (mmoL/L)
BCG – 5.97 ± 1.95 39.07 ± 7.73
MCG 8.00 15.32 ± 4.53## 89.92 ± 6.78##
BLDG 25.00 9.10 ± 3.41* 61.42 ± 7.29*
BHDG 50.00 5.56 ± 1.97** 40.41 ± 9.01**
Compared with the BCG, #P < 0.05, ##P < 0.01; compared with the
MCG, *P < 0.05, **P < 0.01.
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cisplatin-induced renal injury in mice
MDA serum levels signiﬁcantly improved and SOD levels
signiﬁcantly decreased in the MCG, compared with the BCG;
and the difference was statistically signiﬁcant (P < 0.01). MDA
serum levels signiﬁcantly decreased and SOD levels signiﬁ-
cantly increased in the BLD and BHDGs, compared with the
MCG; and the difference was statistically signiﬁcant (P < 0.01)
(Table 2).
3.5. Effect of Bre on MDA and SOD levels in cisplatin-
induced renal cortex injury in mice
MDA levels signiﬁcantly increased and SOD levels signiﬁ-
cantly decreased in the renal cortex of mice in the MCG,Table 2
Effect of Bre on MDA and SOD serum levels in cisplatin-induced renal
injury in mice (mean ± SD, n = 10).
Group Dose (mg/kg) SOD (U/mL) MDA (mmoL/L)
BCG – 9.91 ± 1.43 4.97 ± 0.98
MCG 8.00 4.86 ± 1.11## 11.69 ± 1.03##
BLDG 25.00 5.53 ± 1.57* 6.98 ± 1.04*
BHDG 50.00 6.51 ± 1.21* 6.39 ± 0.77*
Compared with the BCG, #P < 0.05, ##P < 0.01; compared with the
MCG, *P < 0.05, **P < 0.01.compared with the BCG; and the difference was statistically
signiﬁcant (P < 0.01). MDA levels decreased and SOD levels
signiﬁcantly increased in the renal cortex of mice in the BLD
and BHDGs, compared with the MCG (P < 0.05); and level
changes in the BHDG was more signiﬁcant than in the BLDG
(Table 3).
4. Discussion
Cisplatin is one of the most effective antineoplastic drugs
used in clinical practice, and its treatment effect has been
demonstrated in a dose dependent manner. Cisplatin is mainly
excreted in the kidney, and its concentration is much higher in
the epithelium of renal tubules than in blood; thereby causing
serious renal toxicity [9,10]. Injury to renal tubules under low
doses is reversible. However, the accumulation of this drug
under high doses would cause irreversible injury, kidney
failure, or even death [11,12]. Thus, determining how to
improve the quality of chemotherapy, the alleviation of kidney
injury, and the application of the antitumor efﬁciency of
cisplatin has become the focus of research.
Combined therapy is an effective method to improve
chemotherapy efﬁciency in tumor patients. Two kinds of drugs
are combined to improve chemotherapy efﬁciency; however,
toxic reactions have also been increased through this method
[13–15]. In recent years, several ﬂavonoids received extensive
attention for their ability to improve chemotherapy efﬁciency
without causing any toxic reaction [16,17]. Bre is a kind of
ﬂavonoid extracted from lamps of ﬂowers [18,19]. In our
previous study, we found that Bre has a synergistic
antitumor effect with Maryland [20]. Bre can be used to treat
diabetic kidney disease and hypertensive kidney disease
[18,21]. Therefore, we speculate that combining Bre with
cisplatin may lower the toxic reactions of cisplatin while
exerting its antitumor effects. In this study, a cisplatin-
induced renal injury model was established. Different doses
of Bre were given to mice by gavage, and renal pathological
Xiao-Yu Lou et al./Asian Paciﬁc Journal of Tropical Medicine 2015; 8(10): 873–877876injury and blood biochemistry were observed to analyze the
function and mechanism of Bre on cisplatin-induced renal
toxicity.
Cisplatin may generate oxygen free radicals in the body and
induce mitochondrial damage and vacuolization, resulting in
renal injury [22,23]. Free radicals may cause changes in cell
structure and function, thereby affecting tissue and organ
function. GSH-Px can speciﬁcally catalyze the reduction reac-
tion of glutathione to hyperoxide to protect the structure and
function of the cell membrane. In this study, excessive hydrogen
peroxide was generated in the renal cortex after the injection of
cisplatin; which lead to a decrease in GSH-Px activity in the
renal cortex, a decrease in SOD levels and an increase MDA
levels in serum and in the renal cortex, and an increase in BUN
and Scr levels in serum. Normally, there is a dynamic balance of
active oxygen metabolism in the body; and in the pathological
state, a large amount of active oxygen is generated. When
generation rate exceeds the removal limits of antioxidase, lipid
peroxide is accumulated, renal tubules are injured, excretory
function of the kidney is reduced, and ﬁnally resulting in BUN
and Scr retention in vivo. These indicate that renal toxicity and
lipid peroxidation are closely related.
In our study, pathological changes in renal injury induced by
doses of cisplatin and the treatment of diabetic nephropathy with
Bre were used as reference. Mice in the BLD and BHDGs were
given 25 mg/kg and 50 mg/kg doses of Bre, respectively, for
seven days. Results indicate that renal tubular and glomerular
injury in these two treatment groups were mitigated compared
with the MCG; wherein, only a small amount of inﬂammatory
cells was seen, no tissue ﬁbrosis was observed, and cisplatin-
induced brush border injury was alleviated. These results sug-
gest that Bre could increase cell membrane stability and improve
renal condition. Meanwhile, Bre can decrease Scr and BUN
serum levels, as well as decrease MDA levels and increase SOD
levels in serum and in the renal cortex. These suggest that Bre
can improve the body's antioxidant capacity and reduce cell
membrane damage caused by oxidative stress. Thus, Bre may
reduce cisplatin-induced renal toxicity by inhibiting lipid
peroxidation.
In summary, Bre can reduce cisplatin-induced renal toxicity
by inhibiting lipid peroxidation; and this method has good
clinical feasibility. This means that Bre combined with cisplatin
may be applied to tumor patients to improve chemotherapy ef-
ﬁciency in the near future. This study has some limitations. For
example, the experiment in this study only lasted for seven days;
and the extent of recovery after cisplatin-induced renal injury
with a prolonged treatment time remains unclear. Further studies
and long-term experiments are needed.
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